<DOC>
	<DOCNO>NCT01867957</DOCNO>
	<brief_summary>1 . BACKGROUND The newly develop anthrax vaccine GC1109 proven safe effective preclinical study . 2 . OBJECTIVE - To evaluate immunogenicity safety anthrax vaccine GC1109 healthy male volunteer . 3 . STUDY DESIGN - single-blinded - randomize - placebo control - phase 1 study</brief_summary>
	<brief_title>Efficacy Safety Anthrax Vaccine , GC1109</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male subject 18 45 year age time screen visit 2 . 18.5kg/m2 â‰¤BMI &lt; 30kg/m2 time screen visit 3 . Subjects without congenital chronic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>anthrax</keyword>
	<keyword>vaccine</keyword>
	<keyword>bioterrorism</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>